Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samuel Cemaj

Surgical Critical Care Omaha, NE Medical Doctor

NPI 1497869812 CMS profile 975561

1226 S 109Th St, Omaha, NE 68144

Open in the dashboard

General payments

$2,125

21 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samuel Cemaj of Omaha, NE is reported in the CMS Open Payments database as having received $2,125 across 21 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Surgical Critical Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16 1
2024 General $135 1
2023 General $679 7
2022 General $540 5
2021 General $103 1
2020 General $120 1
2019 General $531 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samuel Cemaj
  • Surgical Critical Care median
  • Middle half of Surgical Critical Care
  • National median

In program year 2025, general payments to Samuel Cemaj were reported at $16. Among 1,068 Surgical Critical Care profiles paid that year, the median was $231 and the middle half received between $82 and $1,489.

Show as a table
Year Samuel Cemaj Surgical Critical Care median Middle half National median
2019 $531 $161 $57–$631 $163
2020 $120 $116 $33–$383 $114
2021 $103 $121 $37–$475 $132
2022 $540 $163 $53–$789 $149
2023 $679 $188 $67–$1,031 $160
2024 $135 $216 $80–$1,133 $164
2025 $16 $231 $82–$1,489 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $1,258 12 payments
  2. KLS-Martin L.P. $182 2 payments
  3. Allergan Inc. $130 1 payment
  4. Innovation Technologies Inc $128 1 payment
  5. W. L. Gore & Associates, Inc. $120 1 payment
  6. Portola Pharmaceuticals, Inc. $114 1 payment
  7. Ethicon US, LLC $96 1 payment
  8. Zimmer Biomet Holdings, Inc. $70 1 payment
  9. Boston Scientific Corporation $27 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,125 21 payments
Products named General payments · program years 2019–2025
  1. GRAFIX PL $1,117 10 payments
  2. STRAVIX Extremities & Limb Restoration $950 8 payments
  3. OASIS $369 4 payments
  4. STRAVIX PL $358 3 payments
  5. GRAFIX XC Other Advanced Wound Management $358 3 payments
  6. STRATTICE $130 1 payment
  7. Irrisept $128 1 payment
  8. GRAFIX XC Other Advanced Wound Management $125 1 payment
  9. Stravix Other Advanced Wound Management $125 1 payment
  10. Grafix PRIME $125 1 payment
  11. Other $997 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$4,764

Medicare's payments for the services billed

Medicare patients

37

Average age 74

Services billed

68

21 women, 16 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 43%
Diabetes 38%
Chronic kidney disease 38%
COPD 35%
Atrial fibrillation 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

21 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgical Critical Care in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record